Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The New England Journal of Medicine

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

- PMLiVE

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Will pay $100m upfont and pledges $210m in milestone payments

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

Biogen’s R&D chief Ehlers heads for the exit

Follows multiple late-stage Alzheimer's study failures

- PMLiVE

Biogen loses another pipeline drug to toxicity concerns

Follows discontinuation of Eisai-partnered Alzheimer's drug

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

- PMLiVE

Biogen bounces back with Spinraza early treatment data

Takes battle to Novartis in youngest patients

- PMLiVE

Biogen trumpets safety data for Tecfidera follow-up

Much riding on blockbuster's successor

Biogen Idec building

Biogen’s tofersen shows promise in slowing down ALS

Hope for subset of patients with wasting disease

- PMLiVE

Biogen’s Spinraza overpriced, says ICER

Cost watchdog warns high price puts pressure on US health system

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links